Jubilant Organosys' Bangalore based subsidiary - Jubilant Biosys has entered into a discovery and development collaboration agreement with Endo Pharmaceuticals, a US based specialty pharmaceutical company engaged in R&D and marketing of branded as well as generic medicines. As part o the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of oncology, with a focus on delivering preclinical candidates that could be selected for join clinical development.

Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization. Under an initial three-year agreement, Jubilant will receive from Endo research funding and success-based development milestones and royalties on the successful commercialization of the compounds developed.

Shyam Bhartia chairman & managing director and Hari Bhartia, co-chairman and managing director, Jubilant Organosys, said, "We are pleased to announce his collaboration with Endo Pharmaceuticals, and look forward to the prospect of contributing to Endo's expanding discovery pipeline. We anticipate significant rewards on successful development of compounds and its subsequent commercialization. This partnership continues to demonstrate Jubilant's mission to be India's largest provider of innovative solutions for accelerating global drug development and enabling affordable patient care."

Dr Ivan Gergel, executive vice president, research and development of Endo, said, "We are excited about this opportunity with Jubilant. We look forward to our collaboration with the goal of bringing new therapies and healthcare solutions to patients."